الفهرس 
Hepatocellular carcinomaOnly 14 pages are availabe for public view
 |  | from | 172 |  |  |
| | | from | 172 | | |
Abstract
Liver cirrhosis represents the end stage of several chronic liver injuries. It is characterized by degeneration, regeneration by nodules with loss of lobular architecture, which results in decrease of liver cell mass, portal hypertension and porto-systemic shunt opening.
Aim of the Work: To investigate the diagnostic performance of fibroblast growth factor 19 as a potential novel biomarker for hepatocellular carcinoma for the detection and prognostic stratification of HCC.
Patients and Methods: This was a case control study that was conducted on 90 Egyptian participants aged ≥ 18 years old in Internal medicine - Gastroenterology and Hepatology department Ain Shams University through 6 months.
Results: No statistically significant difference between three groups (control, HCC, CLD) regarding age and sex. There was highly statistically significant difference found between two groups regarding CHILD regarding HB, Platelets, ALT, AST, Albumin, INR and Bilirubin. No statistically significant difference was found between three groups regarding WBCs, creatinine and urea. The mean platelets count was highly significant lower in cirrhotic group than control group but there was no significant difference count the mean platelets count was highly significant lower in cirrhotic group than control group No significant difference was found between HCC and cirrhotic groups regarding platelets count.
Conclusion: FGF19 is promising marker for the diagnosis of HCC.